Resources
BeiGene Medical Europe

ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (ASCO)

 Back View
ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (ASCO)
 ABSTRACT   06/2020
 View

For more information about this resource, please submit a medical information request.

Presented at the 2020 Annual Meeting of the American Socuety of Clinical Oncology (ASCO), May 29 - May 31, 2020

Abstract: 8007

Rating

Rate this resource

Related resources

BeiGene Presents Updated Head to Head Results from Phase 3
BeiGene Presents Updated Head to Head Results from Phase 3
Zanubrutinib - Mode of Action
Zanubrutinib - Mode of Action
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
 Back

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service